pMHC nanomedicine (transplant rejection prevention)

This unnamed research-stage program from Parvus Therapeutics utilizes the company's proprietary peptide-major histocompatibility complex (pMHC) nanomedicine platform, known as Navacims, to prevent organ transplant rejection. The drug candidates consist of iron-dextran nanoparticles displaying multiple copies of disease-specific pMHC complexes. These complexes are designed to engage T cell receptors (TCRs) on alloreactive T cells, reprogramming them into antigen-specific Type 1 regulatory T cells (TR1-like cells). This mechanism induces localized immune tolerance to the transplanted organ antigens without the need for broad, systemic immunosuppression, potentially avoiding the significant side effects and risks of infection associated with standard transplant maintenance therapies.

Other names

Parvus Therapeutics transplant rejection programpMHC nanomedicine for transplant rejection